Hjem › Leverkreft (hepatocellulært karcinom) › Washington
Kliniske studier for Leverkreft (hepatocellulært karcinom) i Washington
15 studier for Leverkreft (hepatocellulært karcinom) søker deltakere på steder i Washington.
Byer i Washington
Offisiell studietekst (engelsk)
The Vanguard Study: Testing a New Way to Screen for Cancer
- Madigan Army Medical Center, Tacoma
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 45 til 75 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06995898Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Research Facility, Seattle
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06726161Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Virginia Mason Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center- Montlake, Seattle
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07227012A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Local Institution - 0083, Seattle
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07291076GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
- Fred Hutchinson Cancer Center, University of Washington, Seattle
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT04864054Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Seattle
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06921785A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Wenatchee Valley Hospital and Clinics, Wenatchee
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 5. aug. 2026 · NCT06330064A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- University of Washington School of Medicine, Seattle
RekruttererFase 2
Alder 8 og eldre · Alle kjønn · Oppdatert 27. jul. 2026 · NCT05503797Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
Rekrutterer
Alder 18 til 75 · Alle kjønn · Oppdatert 17. jun. 2026 · NCT05486572DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA09-0, Puyallup
- USA07-0, Spokane
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. mai 2026 · NCT06953089A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Virginia Mason Medical Center, Seattle
- Summit Cancer Centers - North Spokane, Spokane
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 27. apr. 2026 · NCT05440708Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- American Oncology Network Vista Oncology Division/Physician Partner Associate, Olympia
- Northwest Medical Specialties PLLC (NWMS), Tacoma
RekruttererFase 1
Alder 18 til 65 · Alle kjønn · Oppdatert 16. mar. 2026 · NCT07176650Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
- Seattle Children's Hospital, Seattle
RekruttererFase 1
Alder 1 til 26 · Alle kjønn · Oppdatert 17. feb. 2026 · NCT07148050A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 105, Spokane
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 21. nov. 2025 · NCT05914116SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Seattle
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.